Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence-Reference-Cited by-同舟云学术

Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence

Published:2022-08-04 Issue:11 Volume:24 Page:2071-2080
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Khunti Kamlesh¹^ORCID,Aroda Vanita R.²^ORCID,Bhatt Deepak L.²,Bozkurt Biykem³,Buse John B.⁴,Heerspink Hiddo L.⁵^ORCID,Inzucchi Silvio E.⁶^ORCID,Lam Carolyn S. P.⁷^ORCID,Marx Nikolaus⁸,McMurray John J. V.⁹^ORCID,Solomon Scott D.¹⁰,Kosiborod Mikhail N.¹¹^ORCID

Affiliation:

1. Diabetes Research Centre University of Leicester Leicester UK

2. Brigham and Women's Hospital Harvard Medical School Boston Massachusetts USA

3. Section of Cardiology, Baylor College of Medicine Houston Baylor Houston Texas USA

4. Division of Endocrinology and Metabolism University of North Carolina School of Medicine Chapel Hill North Carolina USA

5. University Medical Center Groningen Groningen Netherlands

6. Section of Endocrinology Yale School of Medicine New Haven Connecticut USA

7. National Heart Centre Singapore and Duke‐National University of Singapore Singapore Singapore

8. Department of Internal Medicine I—Cardiology RWTH Aachen University Aachen Germany

9. Department of Medicine, British Heart Foundation Cardiovascular Research Centre University of Glasgow Glasgow UK

10. Division of Cardiovascular Medicine Brigham and Women's Hospital Boston Massachusetts USA

11. Saint Luke's Mid America Heart Institute University of Missouri‐Kansas City Kansas City Missouri USA

Funder

Biomedical Research Centre

National Institute for Health Research

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14805

Reference68 articles.

1. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

2. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

3. U.S Food and Drug Administration.Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood US2015.http://www.fda.gov/downloads/DrugSafety/UCM446954.pdf. Accessed October 1 2021.

4. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review

5. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials;The Lancet Diabetes & Endocrinology;2024-09

2. Early Identification and Management of Chronic Kidney Disease: A Narrative Review of the Crucial Role of Primary Care Practitioners;Advances in Therapy;2024-08-20

3. Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials;Age and Ageing;2024-08

4. Indirect effects of the COVID-19 pandemic on diagnosing, monitoring, and prescribing in people with diabetes and strategies for diabetes service recovery internationally;Diabetes Research and Clinical Practice;2024-06

5. Applications of SGLT2 inhibitors beyond glycaemic control;Nature Reviews Nephrology;2024-04-26